Your browser doesn't support javascript.
loading
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Furlanetto, J; Eiermann, W; Marmé, F; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; Denkert, C; von Minckwitz, G; Lederer, B; Nekljudova, V; Weber, K; Loibl, S; Möbus, V.
Afiliación
  • Furlanetto J; Department of Medicine and Research, German Breast Group, Neu-Isenburg jenny.furlanetto@gbg.de.
  • Eiermann W; Department of Gynecologic Oncology, Inter-disciplinary Oncological Center, München.
  • Marmé F; Women's Hospital, University Hospital Heidelberg, Heidelberg.
  • Reimer T; Department of Obstetrics and Gynecology Klinikum Südstadt Rostock, Rostock.
  • Reinisch M; Women's Hospital, Kliniken Essen-Mitte, Essen.
  • Schmatloch S; Department of Gynecologic Oncology, Elisabeth-Krankenhaus Brustzentrum, Kassel.
  • Stickeler E; Department of Gynaecology and Obstetrics, Hospital Technische Universität Aachen, Aachen.
  • Thomssen C; Department of Gynecology, Universitiy Hospital Halle, Saale.
  • Untch M; Department of Gynecology, Helios Klinikum Berlin-Buch, Berlin.
  • Denkert C; Institute of Pathology, Charite Berlin, Berlin.
  • von Minckwitz G; Department of Medicine and Research, German Breast Group, Neu-Isenburg.
  • Lederer B; Department of Medicine and Research, German Breast Group, Neu-Isenburg.
  • Nekljudova V; Department of Medicine and Research, German Breast Group, Neu-Isenburg.
  • Weber K; Department of Medicine and Research, German Breast Group, Neu-Isenburg.
  • Loibl S; Department of Medicine and Research, German Breast Group, Neu-Isenburg.
  • Möbus V; Department of Obstetrics and Gynecology, Klinikum Frankfurt -Hoechst, Frankfurt, Germany.
Ann Oncol ; 27(11): 2053-2059, 2016 11.
Article en En | MEDLINE | ID: mdl-27502721
BACKGROUND: In routine clinical practice, chemotherapy doses are frequently capped at a body surface area (BSA) of 2.0 m2 or adjusted to an ideal weight for obese patients due to safety reasons. MATERIALS AND METHODS: Between August 2004 and July 2008, a total of 3023 patients were enrolled in the GAIN study, a randomized phase III adjuvant trial, comparing two types of dose-dense (dd) regimen [epirubicin, docetaxel and cyclophosphamide (iddETC) versus epirubicin and cyclophosphamide (EC) followed by docetaxel (T) plus capecitabine (X)]. We retrospectively evaluated a total of 555 patients with a BMI of ≥30 for safety and outcome. RESULTS: Eighteen percent of all patients were obese: 31% of those received chemotherapy according to an unadjusted BSA. For the remaining patients, BSA was adjusted to ideal weight or was capped at 2.0 m2. A total of 15% of obese patients receiving full (unadjusted) dose of chemotherapy versus 6% of obese patients with an adjusted BSA experienced febrile neutropenia (P = 0.003) and 9% versus 3% high-grade thrombopenia (P = 0.002). Overall, 17% versus 10% had a thromboembolic event (P = 0.017), which was high grade in 13% versus 6%, respectively (P = 0.019), and 3% versus 0.3% high-grade hot flushes (P = 0.013). Dizziness (5% versus 11%; P = 0.016), diarrhea (19% versus 27%; P = 0.033) and an increase in serum creatinine (7% versus 14%; P = 0.019) were higher in the adjusted group. However, no differences in disease-free survival (DFS) and overall survival (OS) were observed between non-obese patients, obese patients receiving full-dose chemotherapy or according to an adjusted BSA [5-year DFS 81% (confidence interval 79% to 83%) versus 82% (75% to 87%) versus 81% (76% to 84%); P = 0.761; 5-year OS 90% (88% to 91%) versus 86% (80% to 91%) versus 88% (84% to 91%); P = 0.143]. CONCLUSION: Obese patients receiving dd chemotherapy according to their real BSA have a higher risk of developing severe toxicities without influencing survival. Therefore, a dose adjustment of intense dd chemotherapy should be carried out to avoid life-threatening complications.
Asunto(s)
Palabras clave
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Relación Dosis-Respuesta a Droga / Obesidad Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Relación Dosis-Respuesta a Droga / Obesidad Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido